Pe mouse anti human cd38

Weekly BLI was performed on MM.1S IV mice until they reached a mean photon flux of 3 × 10⁶ photons/s. Mice were then randomized into untreated and treated cohorts (n = 7/group). Treated mice were provided DARA intraperitoneally (IP) at a therapeutic dose of 16 mg/kg of body weight in 1× PBS. Treatment was administered weekly for 6 weeks in accordance with DARA treatment guidelines [15 ]. Additional BLI was performed twice per week during therapy. Relative bioluminescence was calculated for each time point by dividing photon flux by baseline photon flux prior to therapy. After 6 weeks, mice from treated and untreated cohorts were injected IV with 100 μg of DARA-IRDye800. Mice were imaged on Optix MX3 time-domain diffuse optical imaging system and immediately sacrificed at 7 days post-administration for ex vivo biodistribution and flow cytometry studies as previously described. Analysis of in vivo fluorescent images was performed in ImageJ by measuring MFIs from whole-body ROIs drawn around mice. Normalized fluorescence intensities were calculated by dividing MFIs post-contrast by MFIs prior to DARA-IRDye800 administration. Ex vivo images and flow cytometry data were analyzed as previously described with an additional stain performed with PE mouse anti-human CD38 (BD) for flow cytometry.